VTRS · XBRL financial data

Viatris financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VTRS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	11,946	17,886	16,263	15,427	14,739	14,300
Revenue from contracts with customers	11,820	17,814	16,218	15,388	14,693	14,250
Cost of goods and services sold	8,149	12,311	9,766	8,988	9,116	9,286
Gross profit	3,797	5,576	6,497	6,439	5,624	5,014
Research and development	555	751	—	—	—	—
Selling, general and administrative	3,345	4,529	4,179	4,650	4,426	3,794
Total operating expenses	4,008	5,610	4,882	5,672	5,614	7,677
Operating income (loss)	(211)	(34)	1,615	766	10	(2,663)
Interest expense	498	636	592	573	550	471
Other income (expense)	(13)	6	1,791	10	(83)	(531)
Income tax expense (benefit)	(51)	605	735	148	11	(150)
Earnings per share, basic USD per share	(1.11)	(1.05)	1.71	0.05	(0.53)	(3.00)
Earnings per share, diluted USD per share	(1.11)	(1.05)	1.71	0.05	(0.53)	(3.00)
Weighted average shares, basic millions of shares	601	1,209	1,212	1,200	—	—
Weighted average shares, diluted millions of shares	601	1,209	1,217	1,207	—	—

Fiscal years (VTRS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	844	701	1,260	992	735	1,322
Marketable securities	39	38	35	37	38	41
Accounts receivable	4,844	4,266	3,815	3,700	3,221	3,031
Inventory	5,472	3,978	3,520	3,470	3,854	3,999
Prepaid and other current assets	1,707	1,958	1,811	2,028	1,711	1,436
Total current assets	12,868	10,903	10,635	12,976	9,521	9,789
Property and equipment, net	3,460	3,189	3,025	2,760	2,666	2,614
Right-of-use asset	324	291	259	246	253	271
Goodwill	12,347	12,114	10,426	9,867	9,133	6,755
Total assets	61,553	54,843	50,022	47,686	41,501	37,193
Current portion of long-term debt	2,309	1,878	1,259	1,943	8	1,933
Total current liabilities	10,563	9,884	6,746	7,777	5,779	7,094
Long-term debt	22,429	19,717	18,015	16,188	14,039	12,481
Lease liability, non-current	230	201	181	165	179	178
Total liabilities	38,599	34,350	28,950	27,218	22,865	22,482
Retained earnings (accumulated deficit)	5,361	3,689	5,176	4,640	3,419	(388)
Total liabilities and equity	61,553	54,843	50,022	47,686	41,501	37,193
Common shares outstanding (cover page) millions of shares	1,207	1,210	1,197	1,188	1,194	1,151

Fiscal years (VTRS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Stock-based compensation	79	111	116	181	146	178
Depreciation and amortization	2,216	4,507	3,028	2,741	2,893	2,798
Net cash from operating activities	1,232	3,017	2,953	2,800	2,303	2,316
Purchases of property and equipment	243	457	406	377	326	379
Net cash from investing activities	(301)	(118)	1,521	(764)	1,801	(428)
Proceeds from issuing common stock	0	0	3	3	3	3
Share repurchases	0	0	0	250	250	501
Proceeds from long-term debt	983	1,710	1,876	0	0	0
Repayments of long-term debt	2,484	4,201	3,663	1,250	3,714	0
Net cash from financing activities	(606)	(3,012)	(3,878)	(2,302)	(4,330)	(1,294)
Net change in cash	359	(144)	556	(269)	(258)	612

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Viatris	1,789	3,735	899*	1.1B	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
United Therapeutics	1,189	833	307*	42.6M	—	Q3 FY26 10-QSep 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
BeOne Medicines	5,781	1,890	509*	1.5B	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	616	198	(416)*	216.3M	9.4 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 8:24 AM ET. The filing on SEC.gov is the record.